High Expectations for ICSE Japan
News Apr 12, 2006
The challenges facing Clinical Research Organisations (CRO’s) wishing to target the highly evolved Japanese pharmaceutical market will be the principal theme at the ‘Overseas CRO Marketing Seminar’ being held at the International Contract Services Expo Japan(ICSE) (24-26 April, Big Sight, Tokyo).
The seminar, which is free of charge, takes place on 26th April and will feature presentations from leading Swiss and Indian CRO’s, PSI Pharma Support International and Jubilant Organosys Ltd. ICSE Japan organiser, CMP Information (CMPi), reports an unprecedented level of interest in the conference, with over 100 delegates having pre-registered for each session.
Now in its second year, ICSE Japan runs alongside CPhI Japan, the nation’s premier annual pharma services event, which will host over 450 exhibitors. 14,000 visitors – up from close to 12,200 last year - are expected to attend.
Valerie Droogleever Fortuyn, ICSE Marketing Manager, comments, "The interest generated by the free seminars and the very positive reception that ICSE received at last year’s show mean that we have very high expectations for ICSE Japan 2006."
"We intend to establish ICSE Japan as the key annual industry event for companies wishing to promote new products, outsourcing solutions, R&D, validation or quality assurance services to the Japanese pharmaceutical market."
In total, CPhI Japan 2006 offers visitors and delegates a menu of over 90 sessions and presentations covering a wide range of pharma ingredients trends, issues, topics and technologies.
The show is staged by CMPi, with its Japanese company CMP Japan Co. Ltd., and co-organised by the publishers of Japan’s Chemical Daily and Japan Chemical Week.
The first in a series of ICSE events scheduled for 2006, ICSE Japan is followed by ICSE China, (27-29 June, Pudong, Shanghai) and ICSE Worldwide (3-5 October, Paris-Nord Villepinte, France).
CMPi recently announced plans to take the ICSE show to the US for the first time in 2007, where it will run alongside INFORMEX®(San Francisco, February 13-16).
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE